Correlation Between Molecular Partners and ZyVersa Therapeutics
Can any of the company-specific risk be diversified away by investing in both Molecular Partners and ZyVersa Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Molecular Partners and ZyVersa Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Molecular Partners AG and ZyVersa Therapeutics, you can compare the effects of market volatilities on Molecular Partners and ZyVersa Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Molecular Partners with a short position of ZyVersa Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Molecular Partners and ZyVersa Therapeutics.
Diversification Opportunities for Molecular Partners and ZyVersa Therapeutics
0.14 | Correlation Coefficient |
Average diversification
The 3 months correlation between Molecular and ZyVersa is 0.14. Overlapping area represents the amount of risk that can be diversified away by holding Molecular Partners AG and ZyVersa Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on ZyVersa Therapeutics and Molecular Partners is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Molecular Partners AG are associated (or correlated) with ZyVersa Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of ZyVersa Therapeutics has no effect on the direction of Molecular Partners i.e., Molecular Partners and ZyVersa Therapeutics go up and down completely randomly.
Pair Corralation between Molecular Partners and ZyVersa Therapeutics
Given the investment horizon of 90 days Molecular Partners AG is expected to generate 0.49 times more return on investment than ZyVersa Therapeutics. However, Molecular Partners AG is 2.06 times less risky than ZyVersa Therapeutics. It trades about 0.0 of its potential returns per unit of risk. ZyVersa Therapeutics is currently generating about -0.15 per unit of risk. If you would invest 567.00 in Molecular Partners AG on August 24, 2024 and sell it today you would lose (25.00) from holding Molecular Partners AG or give up 4.41% of portfolio value over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Together |
| Strength | Insignificant |
| Accuracy | 100.0% |
| Values | Daily Returns |
Molecular Partners AG vs. ZyVersa Therapeutics
Performance |
| Timeline |
| Molecular Partners |
| ZyVersa Therapeutics |
Molecular Partners and ZyVersa Therapeutics Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Molecular Partners and ZyVersa Therapeutics
The main advantage of trading using opposite Molecular Partners and ZyVersa Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Molecular Partners position performs unexpectedly, ZyVersa Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ZyVersa Therapeutics will offset losses from the drop in ZyVersa Therapeutics' long position.| Molecular Partners vs. ZyVersa Therapeutics | Molecular Partners vs. Sonnet Biotherapeutics Holdings | Molecular Partners vs. Zura Bio Limited | Molecular Partners vs. Phio Pharmaceuticals Corp |
| ZyVersa Therapeutics vs. Cns Pharmaceuticals | ZyVersa Therapeutics vs. Immix Biopharma | ZyVersa Therapeutics vs. Hepion Pharmaceuticals | ZyVersa Therapeutics vs. Zura Bio Limited |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.
Other Complementary Tools
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals |